Beam Therapeutics Inc (BEAM) is set for another landmark as it hit the volume of 3.38 million

Beam Therapeutics Inc (NASDAQ: BEAM) established initial surge of 4.83% at $26.06, before settling in for the price of $24.86 at the close. Taking a more long-term approach, BEAM posted a 52-week range of $16.95-$49.50.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 43297.50%. Meanwhile, its Annual Earning per share during the time was 5.58%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -176.27%. This publicly-traded company’s shares outstanding now amounts to $81.63 million, simultaneously with a float of $76.79 million. The organization now has a market capitalization sitting at $2.14 billion. At the time of writing, stock’s 50-day Moving Average stood at $24.39, while the 200-day Moving Average is $26.67.

Beam Therapeutics Inc (BEAM) Ownership Facts and Figures

Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Beam Therapeutics Inc industry. Beam Therapeutics Inc’s current insider ownership accounts for 6.71%, in contrast to 78.65% institutional ownership. According to the most recent insider trade that took place on Apr 02 ’24, this organization’s Chief Medical Officer sold 16,530 shares at the rate of 30.54, making the entire transaction reach 504,851 in total value, affecting insider ownership by 70,060. Preceding that transaction, on Apr 01 ’24, Company’s CEO sold 18,102 for 32.13, making the whole transaction’s value amount to 581,617. This particular insider is now the holder of 1,058,343 in total.

Beam Therapeutics Inc (BEAM) Earnings and Revenue Records

Beam Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -176.27% and is forecasted to reach -4.76 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -3.70% through the next 5 years, which can be compared against the 5.58% growth it accomplished over the previous five years trading on the market.

Beam Therapeutics Inc (NASDAQ: BEAM) Trading Performance Indicators

Let’s observe the current performance indicators for Beam Therapeutics Inc (BEAM). It’s Quick Ratio in the last reported quarter now stands at 5.99. The Stock has managed to achieve an average true range (ATR) of 1.50. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 5.94.

In the same vein, BEAM’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.78, a figure that is expected to reach -1.14 in the next quarter, and analysts are predicting that it will be -4.76 at the market close of one year from today.

Technical Analysis of Beam Therapeutics Inc (BEAM)

Now, what If we examine the latest scores posted by [Beam Therapeutics Inc, BEAM]. During the last 5-days, its volume was better the volume of 1.36 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 72.52% While, its Average True Range was 1.56.

Raw Stochastic average of Beam Therapeutics Inc (BEAM) in the period of the previous 100 days is set at 18.21%, which indicates a major fall in contrast to 69.53% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 41.30% that was lower than 77.07% volatility it exhibited in the past 100-days period.